Psychedelic Trials Face a Methodological Reckoning as Blinding Failures and Design Gaps Threaten Regulatory Success
Key Insights
A systematic review of 112 psychedelic RCTs found blinding failure rates exceeding 90%, with only 29.5% of trials evaluating blinding integrity and 57.1% acknowledging it as a limitation.
The FDA's 2024 rejection of MDMA-assisted therapy for PTSD and its 2023 Complete Response Letter for COMP360 both cited functional unblinding as a core evidentiary concern.
Expectancy effects may be an intrinsic part of psychedelic therapy's mechanism, raising fundamental questions about whether the FDA's drug approval architecture can accommodate drug-plus-context systems.
The psychedelic research field is generating some of the most striking efficacy signals in psychiatric drug development — a 70% remission rate for postpartum depression (search) after a single dose of luvesilocin (search), a 75% response rate for elunetirom (search) in bipolar depression (search), and Breakthrough Therapy designations from the FDA. Yet beneath these numbers lies a methodological architecture that, by the field's own admission, is fundamentally compromised. A systematic review of 112 randomized clinical trials of psychedelics as psychiatric interventions found that blinding failure rates frequently exceeded 90% among both participants and raters, with only 29.5% of studies even evaluating whether the blind held. The question now confronting regulators is not whether these compounds produce therapeutic effects, but whether the evidence base can support approval when the blind is broken from the first dosing session.
The Broken Blind: A Structural Problem, Not an Edge Case
In a standard randomized controlled trial, blinding ensures that neither participant nor assessor knows which arm the subject occupies, distributing expectancy effects equally across groups. In psychedelic trials, this assumption collapses entirely. A participant receiving 25mg of psilocybin undergoes a complete perceptual and cognitive alteration lasting four to six hours. A participant receiving a 100mg niacin active placebo experiences flushing and tingling. The experiential difference is not subtle, and there is no statistical adjustment that can compensate for participants correctly identifying their assignment 90% of the time.
The consequence is what can be termed the Expectancy Inflation Principle: in any trial where functional unblinding exceeds 80%, the primary efficacy endpoint absorbs a directional bias whose magnitude cannot be estimated from the trial data alone. A trial published in Psychological Medicine examining psilocybin versus escitalopram for depression found that pre-treatment expectancy scores were predictive of outcome — meaning some portion of the measured antidepressant effect was being generated by what participants believed before the drug touched their receptor. When the blind is broken and that belief is confirmed in real time, the expectancy signal amplifies, and the effect size reported at week six becomes a composite of pharmacology and psychology that cannot be decomposed.
Regulatory Precedent: The MDMA Rejection and Its Implications
The FDA's August 2024 rejection of Lykos Therapeutics (search)' NDA for MDMA-assisted therapy for PTSD made functional unblinding a load-bearing element of the agency's reasoning. Participants in the Phase 3 MAPP1 and MAPP2 trials reported unmistakable subjective drug effects, and blinding assessment data confirmed near-total identification. The Complete Response Letter requested an additional Phase 3 trial — a decision that effectively declared the existing evidence base uninterpretable for effect size estimation.
The structural parallel to COMPASS Pathways' psilocybin program is direct. COMP360 received FDA Breakthrough Therapy designation for treatment-resistant depression (search) in October 2018, but Breakthrough designation is granted on early evidence of substantial improvement over existing therapy, not on evidence that the blind held. Both compounds produce unmistakable subjective experiences. Both have efficacy literatures generating headlines. And both now face the same underlying evidentiary question: how much of the signal is drug, and how much is the participant knowing they received the drug in a highly supportive therapeutic context designed to maximize expectancy of healing?
The Dissent: Expectancy as Mechanism, Not Noise
Balázs Szigeti, PhD, a clinical data scientist at UCSF's Translational Psychedelic Research Program, has advanced a counterargument with significant regulatory implications. His position is that the expectancy effect may be a genuine component of the therapeutic mechanism — that for psychedelic-assisted therapy, the drug's ability to induce a state of heightened suggestibility and openness is not noise contaminating the pharmacological signal, but part of what the therapy actually does. Under this framing, attempting to strip expectancy out of the outcome measure may be scientifically incoherent.
The argument carries force but also a consequence the field tends to understate: if expectancy is part of the mechanism, then the product being approved cannot be described simply as a drug. It is a drug-plus-context system, and the FDA's approval architecture was not designed for that. The agency's 2019 guidance on placebos and blinding in randomized controlled cancer trials acknowledges that blinding failure increases risk of bias and instructs sponsors to assess blinding integrity — but that guidance was written for oncology. No psychedelic-specific blinding framework exists.
Sex-Specific Design Gaps Compound the Evidence Problem
The methodological gaps extend beyond blinding. Susanne Prinz, reporting from ICPR 2026, identified that menstrual cycle phase, hormonal status at baseline, contraceptive use, and menopausal status are still not being systematically captured in psychedelic trial design. This is particularly acute for drugs like luvesilocin (search), a synthetic psilocybin derivative being developed specifically for postpartum depression (search) — a female-only indication. Grace Blest-Hopley's work, presented at ICPR 2026, argues that sex-specific factors shape subjective experience, safety, tolerability, and outcomes, and that clinical settings need to account for gender-specific themes in preparation, informed consent, therapeutic framing, and group composition.
The Therapy Model Fork
Matthew Wall's declaration that psilocybin combined with cognitive behavioral therapy represents "the future" and that the older non-directive therapy model "is going to be replaced" introduces a further complication. The non-directive model — grounded in the assumption that the compound itself, given in a supportive but minimally structured environment, drives the therapeutic effect — has been the dominant framework through the MAPS MDMA trials and Imperial College's psilocybin depression work. If Wall is correct that structured CBT provides the scaffolding that converts a pharmacologically induced neuroplastic window into durable behavioral change, then studies run under non-directive protocols are not measuring the same intervention as studies run under CBT-integrated protocols. They are not directly comparable, and the field is about to have both kinds of data in circulation simultaneously.
Safety and the Trial-to-Practice Gap
Rosana Freitas shared data indicating that approximately 5.8% of cases in randomized controlled trials experienced transient euphoria or dysphoria in controlled clinical settings, with higher risk in naturalistic and unsupervised settings, particularly in bipolar I disorder. No evidence of de novo bipolar induction was found, and symptoms were acute and self-limited. That safety profile, however, was observed in controlled settings with screened populations and trained staff — conditions that required, as Ben Spielberg's experience at Stella Mental Health demonstrated, DEA Schedule 1 registration, physical DEA site visits, GCP certifications, and extensive infrastructure buildout. The 5.8% adverse event rate in controlled trials is unlikely to be the rate observed in routine clinical practice, and the gap between trial conditions and post-approval deployment remains largely unaddressed.
The FDA now faces a decision that will define psychedelic regulatory science for the next decade. Whatever determination it makes on the next psilocybin NDA will implicitly set the standard for how much functional unblinding an approval-grade evidence package can contain. There is no guidance document that answers that question. There is no precedent from an approved compound with a comparable blinding failure rate. The agency will have to make a judgment call about how to read an efficacy estimate that was, by the field's own admission, built on a broken blind.